Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | BACE1 | P56817 | 8/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112199 | 0.78 | PGR (0.65) | PGRCHEK1 | |
| SCHEMBL5499012 | 0.72 | PGR (0.41) | PGRBACE1CTSDBRD4CHEK1 | |
| SCHEMBL5509127 | 0.70 | PGR (0.37) | PGRBACE1CTSDBRD4CHEK1 | |
| SCHEMBL5111383 | 0.65 | PGR (0.69) | PGR | |
| SCHEMBL11555464 | 0.64 | BRD4 (0.54) | PGRBACE1BRD4CHEK1 | |
| SCHEMBL4849305 | 0.64 | PGR (0.47) | PGRBACE1CTSD | |
| SCHEMBL5506294 | 0.64 | PGR (0.65) | PGR | |
| SCHEMBL5868926 | 0.63 | PGR (0.48) | PGRBACE1CTSDCHEK1 | |
| SCHEMBL4847682 | 0.63 | PGR (0.72) | PGR | |
| SCHEMBL3920748 | 0.62 | BRD4 (0.55) | PGRBRD4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | claimed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | claimed |
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | NR3C2, MC2R, NR3C1 | PGR 194/4885BACE1 2198/4885CTSD 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.